Stockscreener 앱 받기
58.13
2.99%
1.69
시간 외 거래:
58.02
-0.11
-0.19%
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination - Insider Monkey
Bristol Myers Squibb (BMY) Joins Defensive Value Indexes, Is It Still 8% Undervalued? - simplywall.st
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Bristol-Myers Squibb Hires Lobbyist on Drug Pricing - Legis1
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Investigations Launched into Bristol Myers Squibb (BMY) and Othe - GuruFocus
Bristol, Merck, AbbVie face House committee probe over China trials - Seeking Alpha
Beeline ups its Series A round for immune drug work - BioPharma Dive
Is Bristol-Myers Squibb Company (BMY) Stock at Risk From Proposed Medicare Drug Price Negotiation Updates? - Insider Monkey
Bristol Myers Squibb adjusts its growth profile as FTSE Russell reshapes indexes. Dividend and earni - AD HOC NEWS
Exclusive: House China panel questions Bristol Myers, Pfizer and others on trial sites - Endpoints News
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol Myers Squibb updates strategy for Zeposia, shares react to pipeline focus - AD HOC NEWS
Bristol Myers Squibb adjusts expectations on key cancer drug, shares react to analyst debate - AD HOC NEWS
Chemung Canal Trust Co. Increases Position in Bristol Myers Squibb Company $BMY - MarketBeat
Camzyos from Bristol-Myers Squibb Co.targeted heart failure therapy reshapes daily routines - Ad-hoc-news.de
The Opdivo from Bristol-Myers Squibb Co.PD-1 blocker reshapes melanoma therapy - Ad-hoc-news.de
Bristol-Myers Squibb Co (BMY) Stock Up 3.9% but GF Value Says Ov - GuruFocus
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
OmniStar Financial Group, Inc.'s Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Play with Cautionary Notes - ChartMill
Bristol-Myers Squibb focuses on analyst expectations, shares in S&P 500 spotlight - Ad-hoc-news.de
Bristol Myers Squibb clears key cancer drug hurdle, shares in focus after FDA panel backing - Ad-hoc-news.de
BMYBristol-Myers Squibb Co Volatility & Greeks - Finviz
Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb -- Barrons.com - Moomoo
Bristol Myers Follows Novartis, Sues Arkansas Over Pharmacy Law - Bloomberg Law News
Bristol Myers Squibb sets next earnings date, shares trade steadily on NYSE - Ad-hoc-news.de
Opdivo from Bristol-Myers Squibb Co.immunotherapy mainstay with new combo data - Ad-hoc-news.de
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Bristol-Myers Squibb Company (BMY) and SystImmune Announce Results from Analyses of Iza-bren Studies - Insider Monkey
Bristol Myers Squibb weighs dividend reset, shares trade near recent lows - AD HOC NEWS
3 Reasons to Buy Bristol Myers Squibb Stock - The Motley Fool
Bristol-Myers Squibb Company (BMY) Stock Analysis: Exploring the 16.81% Upside Potential for Investors - DirectorsTalk Interviews
Bristol-Myers Squibb Co (BMY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bristol-Myers Squibb Co (CELG_r) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now - Kavout | AI
Bristol-Myers Squibb StockLong-term pipeline and business model under review - AD HOC NEWS
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
Bristol-Myers Squibb Co (CELG_r) Institutional Confidence - TradingKey
Bristol-Myers Squibb Co (CELG_r) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bristol-Myers Squibb Co (CELG_r) Valuation: PE, PB & Fair Value Analysis - TradingKey
CHEMUNG CANAL TRUST CO's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Co (CELG_r) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bristol-Myers Squibb Company: Target Price Consensus and Analysts Recommendations | BMY | US1101221083 - marketscreener.com
Bristol-Myers Squibb (BMY) Maintains Quarterly Dividend at $0.63 per Share - GuruFocus
Bristol-Myers Squibb Co (CELG_r) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Faithward Advisors, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb (BMY) Stock Could Be 12.2% Undervalued on Pipeline and Margin Hopes - Yahoo Finance
Measured Wealth Private Client Group, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Co (BMY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bristol-Myers Squibb Co (BMY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bristol-Myers Squibb Co (CELG_r) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bristol Myers Squibb declares $0.63 quarterly dividend - Investing.com
Bristol Myers Squibb declares $0.63 quarterly dividend By Investing.com - Investing.com Canada
Bristol-Myers Squibb Co (CELG_r) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bristol Myers Squibb Appoints Mayada Al-Ahmad as General Manager for Saudi Arabia & Gulf Countries - PR Newswire UK
BREYANZI® CAR T Cell Therapy Monitoring and Activity Updates Approved in Canada - PR Newswire Canada
Bristol-Myers Squibb Co (BMY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bristol-Myers Squibb Co (BMY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Russell Investments Group Ltd. Raises Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Can BMY's Camzyos Strengthen Its Cardiovascular Portfolio? - Yahoo Finance
Bristol-Myers Squibb—ad spending, facts and profile - Ad Age
Psoriasis around the world - Bristol Myers Squibb
David Elkins - Bristol Myers Squibb
1.84%
자본화:
|
볼륨(24시간):